Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Pediatric Kidney Transplant Recipients Compared to Dialysis Patients and Healthy Children

NCT05465863 is registered in ClinicalTrials.gov with Istanbul University - Cerrahpasa as lead sponsor.

NCT NCT05465863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05465863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Pediatric Kidney Transplant Recipients Compared to Dialysis Patients and Healthy Children
Lead sponsor
Istanbul University - Cerrahpasa
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2021
Completion date
March 1, 2022
Enrollment
101 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease 5d, chronic kidney disease 5t